Golding, Elke M., and Tara E. Kepler. Role of estrogen in modulating EDHF-mediated dilations in the female rat middle cerebral artery. Am J Physiol Heart Circ Physiol 280: H2417-H2423, 2001.-We tested the hypothesis that endothelium-derived hyperpolarizing factor (EDHF) plays a less dominant role in the female cerebrovasculature. The contribution of EDHF to the ATP-mediated dilation was determined in middle cerebral arteries (MCAs) isolated from male and female rats. Four groups of rats were tested: intact male (n ϭ 12), intact female (n ϭ 13), estrogen-treated ovariectomized female (n ϭ 13), and vehicle-treated ovariectomized female (n ϭ 20) rats. Maximal dilation to ATP was similar in all groups. However, in the presence of N -nitro-L-arginine methyl ester (L-NAME, 3 ϫ 10 Ϫ5 M) and indomethacin (10 Ϫ5 M), the maximal dilation to ATP was significantly reduced in intact female (24 Ϯ 9%) and estrogen-treated ovariectomized female (29 Ϯ 9%) rats compared with intact male (95 Ϯ 4%) and vehicle-treated ovariectomized female (96 Ϯ 2%) rats. The ATP-mediated dilation in L-NAME-and indomethacintreated MCAs isolated from male and ovariectomized female rats was inhibited by charybdotoxin (10 Ϫ7 M), an inhibitor of large-conductance Ca 2ϩ -sensitive K ϩ channels. We have defined EDHF as the L-NAME-and indomethacin-insensitive component of the ATP-mediated dilation. Our findings indicate that EDHF-mediated dilations are negligible in the female rat MCA; these dilations can be significantly enhanced after ovariectomy, suggesting that this effect is mediated by estrogen.
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gender; vascular ESTROGEN HAS RECEIVED CONSIDERABLE attention recently as a potential therapeutic agent in various pathophysiological states. Although the mechanisms by which estrogen mediates its protective effects are multifactorial, the endothelium has been shown to play a pivotal role (see Ref. 12 for review). Endothelial cells play a fundamental role in regulating vascular resistance and blood flow through their ability to produce vasodilators such as nitric oxide (NO) and prostacyclin. In addition to NO and prostacyclin, a third vasodilator, known as endothelium-derived hyperpolarizing factor (EDHF), has recently been described in the cerebrovasculature (21) and periphery (5) . EDHF is known to hyperpolarize and relax vascular smooth muscle predominantly through activation of Ca 2ϩ -dependent K ϩ (K Ca ) channels. Although its identity remains elusive, this "eternally deceptive hyperpolarizing factor" has recently sparked much attention (7) . In the present study, we have defined EDHF as the N -nitro-L-arginine methyl ester (L-NAME)-and indomethacin-insensitive component of the dilation to luminal application of ATP, mediated predominantly through activation of K Ca channels.
Although estrogen has been shown to upregulate NO (11, 13) and prostacyclin (1) , no studies have investigated the effect of estrogen on EDHF in the cerebrovasculature. The justification for such studies is well documented. First, there is evidence in the periphery (6) and cerebral circulation (20) that EDHF plays an important role in controlling vascular resistance. Second, EDHF acts in a compensatory manner in endothelial NO synthase (eNOS)-knockout mice, where eNOS is absent (8, 16) . Third, upregulation of EDHF in the cerebrovasculature has been reported after ischemiareperfusion (9) . These studies point to the fact that an equipoise between NO and EDHF may exist, such that, in the absence of NO, EDHF may assume a compensatory role. Given that NO is upregulated in females, we tested the hypothesis that EDHF-mediated dilations play a less dominant role in the cerebrovasculature of females than in males and that this effect is mediated by estrogen.
MATERIALS AND METHODS
Experiments were carried out in strict accordance with National Institutes of Health guidelines for the care and use of laboratory animals and were approved by the Animal Protocol Review Committee at Baylor College of Medicine.
Surgery
Experiments were performed on age-matched (70-90 days old) male (275-324 g) and female (200-224 g) Long-Evans rats. All surgical procedures were undertaken under aseptic conditions. Animals were secured to a nose cone and allowed to breathe spontaneously (2% isoflurane). A heating pad and a temperature controller (Harvard Apparatus) were used to maintain rectal temperature at 37°C. A bilateral ovariectomy was then performed (17) . A dorsal incision was made, and a mini-osmotic pump (model 2004, Alza, Palo Alto, CA) was subcutaneously implanted to deliver 17␤-estradiol or 50% DMSO-0.045% NaCl (vehicle). 17␤-Estradiol was adminis-tered at a physiological dose of 4 g ⅐ kg Ϫ1 ⅐ day Ϫ1 . Validation of our model of ovariectomy and estrogen treatment consisted of 1) monitoring body weight, 2) measuring plasma estradiol concentrations, and 3) obtaining vaginal smears. After completion of surgery, the animals' ears were tagged, wounds were sutured, and the animals were returned to the holding facility for 2 wk.
Harvesting and Mounting Cerebral Vessels
Animals were anesthetized with isoflurane and then decapitated. The brain was removed from the cranium and placed in ice-cold physiological salt solution (PSS). The middle cerebral artery (MCA) was carefully harvested, cleaned of surrounding connective tissue, and cannulated with micropipettes in an arteriograph as described elsewhere in detail (3). PSS was circulated abluminally and perfused luminally. Monitoring of intraluminal pressure was performed from in-line transducers that were connected to two strain gauge panel meters (Omega, Stamford, CT). Once mounted, vessels were tested for leaks by clamping the proximal and distal tubing, and intraluminal pressure was monitored. Vessels that did not maintain a steady pressure were discarded. Transmural pressure was set at 85 mmHg with a flow of 200 l/min through the lumen, and the vessels were allowed to equilibrate for 1 h. During this time, the vessels develop spontaneous tone by constricting from their fully dilated diameter at initial pressurization. After the development of tone, the experiment was initiated (see Experimental Protocol).
Measurement of MCA Diameter
Changes in vessel diameter were observed with an inverted microscope (Nikon) equipped with a videocamera and monitor. Outer diameters were measured directly online from the video monitor (final magnification ϫ600). Dynamic changes in vessel diameter were digitized (post hoc) using image-analysis software (Optimas, Bothell, WA), with an acquisition frequency of 1.1 Hz allowed.
Experimental Groups
Four groups of rats were used in the present study: 1) intact male, 2) intact female, 3) estrogen-treated ovariectomized female, and 4) vehicle-treated ovariectomized female rats. Ovariectomy was performed and drug treatment was initiated 2 wk before isolation of the cerebral vessels.
Measurement of Plasma Estradiol
Immediately after decapitation, trunk blood (3 ml) was obtained from all animals. The blood was centrifuged for 3 min at 8,000 rpm, and the resulting plasma was frozen at Ϫ15°C. 17␤-Estradiol was measured at a later time using an ultrasensitive RIA (Diagnostic Systems Laboratory, Webster, TX).
Experimental Protocol
Experiments were conducted using isolated MCAs by luminal application of ATP, an agonist of the P2Y 2 purinoceptor, which elicits a dilation in male cerebral vessels through the production of NO and EDHF (21) . A concentration-response curve (CRC) to luminal application of ATP (10 Ϫ8 -10 Ϫ4 M) was determined in all four groups. Only one CRC to ATP was conducted for each vessel to avoid tachyphylaxis. In some vessels, dilations to 10 Ϫ6 M ATP were assessed before and after removal of the endothelium (10 ml air) to confirm that the entire response was mediated by the endothelium.
At the end of the experiment, integrity of the smooth muscle was confirmed using 10 Ϫ5 M S-nitroso-N-acetylpenicillamine (SNAP). In other vessels, the CRC to ATP was conducted in the presence of L-NAME (3 ϫ 10 Ϫ5 M) and indomethacin (10 Ϫ5 M) to determine the non-NO, non-prostacyclin component of the dilation. Such a dilation is consistent with an EDHF response. In vessels exhibiting a non-NO, non-prostacyclin dilation, charybdotoxin (10 Ϫ7 M) was delivered abluminally to inhibit the large-conductance KCa channels. Experiments were terminated with Ca 2ϩ -free PSS to determine the maximum dilation of the vessel.
Reagents and Drugs
The PSS consisted of (in mM) 119 NaCl, 24 NaHCO3, 4.7 KCl, 1.18 KH2PO4, 1.17 MgSO4, 1.6 CaCl2, 5.5 glucose, and 0.026 EDTA. It was gassed with 5% CO2-21% O2-balance N2.
After the solution was gassed, the pH of the buffer was ϳ7.40. All drugs were purchased from Sigma (St. Louis, MO) with the exception of MAHMA NONOate, which was purchased from Alexis Biochemicals (San Diego, CA). Stock solutions of ATP (10
, and charybdotoxin (2 ϫ 10 Ϫ5 M) were prepared in distilled water, aliquotted, and then frozen. A stock solution of indomethacin (10 Ϫ2 M) was prepared in a solution of Na2CO3 and distilled water (1:1 by weight). A stock solution of 6-(2-hydroxy-1-methyl-2-nitrosohydrazino)-N-methyl-1-hexanamine (MAHMA NONOate) was prepared in 0.01 M NaOH.
Data Analysis and Calculations
Values are means Ϯ SE. Absolute diameter comparisons were made using a one-way ANOVA followed by a Fisher test for multiple comparisons. For CRC to ATP, the results are presented as a percentage of the maximum diameter of the MCA, as calculated according to Eq. 1
where D ATP is the diameter of the MCA after luminal administration of ATP, D base is the baseline diameter of the MCA before addition of ATP, and D max is the maximal diameter of the MCA in the presence of Ca 2ϩ -free PSS (with 1 mM EGTA). Sigma Plot software (Jandel Scientific, San Rafael, CA) was used to fit individual CRCs for ATP to a sigmoidal curve with the formula
where y is the dilation of the MCA for a given concentration of ATP, x is the ATP concentration, a is the maximal dilation, c is the concentration of agonist necessary to produce 50% of the maximal dilation (EC 50), and b is the Hill coefficient. Equation 2 was solved for x(EC50), given that y was one-half of the maximal dilation.
In the presence of L-NAME and indomethacin, MCA diameter responses to ATP were analyzed using two different methods. Because these responses were very dynamic, two analysis methods provided further validation and increased confidence in our findings. Diameter changes were first analyzed by calculating a time-weighted mean from the observed maximum and minimum diameters during the first minute of drug exposure. The diameter responses were then digitized using Optimas software and integrated using Sigma Plot software during the first 5 min of drug exposure. This al-lowed us to take into consideration the duration, amplitude, and dynamic nature of the responses.
Statistical comparisons of body weight changes were performed using a two-way ANOVA with repeated measures. Comparisons of plasma estradiol concentration and EC 50 values were made using a one-way ANOVA. Statistical comparisons of the CRC to ATP were performed using a two-way ANOVA with repeated measures. Post hoc comparisons were made using a Student-Newman-Keuls test. Differences were considered significant at P Ͻ 0.05.
RESULTS

Model Validation
Body weight. Changes in body weight over the 2-wk period are shown in Fig. 1 . Intact female and estrogentreated ovariectomized female rats showed a similar increase in body weight of 3 Ϯ 1 and 4 Ϯ 2%, respectively (not significant; 2-way repeated-measures ANOVA). Intact male and vehicle-treated ovariectomized female rats also demonstrated a similar increase in body weight of 16 Ϯ 2 and 14 Ϯ 1%, respectively, that was significantly greater than that of intact female and estrogen-treated ovariectomized female rats (P Ͻ 0.05, 2-way repeated-measures ANOVA).
Plasma estrogen. Plasma estrogen values of all experimental groups are shown in Table 1 . Intact female and estrogen-treated ovariectomized female rats had significantly higher plasma 17␤-estradiol concentrations than intact male and vehicle-treated ovariectomized female rats (P Ͻ 0.05, 1-way ANOVA). There was no significant difference in plasma 17␤-estradiol concentration between intact female and estrogentreated ovariectomized female rats, suggesting that we had successfully restored physiological levels of estrogen in ovariectomized animals. Furthermore, there was no significant difference in plasma 17␤-estradiol levels in intact male and vehicle-treated ovariectomized female rats, indicating successful removal of physiological levels of estrogen in these latter animals.
EDHF-Mediated Dilations
After the development of tone, the resting MCA diameters were similar among the groups: 205 Ϯ 4, 212 Ϯ 9, 219 Ϯ 5, and 218 Ϯ 7 m in intact male, intact female, vehicle-treated ovariectomized female, and estrogen-treated ovariectomized female rats, respectively. The dilation to luminal application of ATP in all vessels is shown in Fig. 2 . Vessel diameter measurements were calculated using a time-weighted mean Fig. 1 . Change in body weight over 2 wk in intact female, estrogentreated ovariectomized female (OVX/E2), vehicle-treated ovariectomized female (OVX/Vehicle), and intact male rats. Change in body weight was significantly greater in OVX/Vehicle and intact male rats than in intact female and OVX/E2 animals: *P Ͻ 0.05 (1-way repeated-measures ANOVA). Values are means Ϯ SE; n, no. of rats. OVX/E2, estrogen-treated ovariectomized female rats; OVX/Vehicle, vehicle-treated ovariectomized female rats. * Significantly higher than intact male and vehicle-treated ovariectomized female rats (P Ͻ 0.05, 1-way ANOVA). Fig. 2 . Concentration-response curves to luminal application of ATP in middle cerebral arteries (MCAs) isolated from intact male (n ϭ 5), intact female (n ϭ 6), estrogen-treated ovariectomized female (n ϭ 6), and vehicle-treated ovariectomized female (n ϭ 7) rats. Dilation to 10 Ϫ6 M ATP was significantly reduced in ovariectomized female rats with estrogen and vehicle treatment: *P Ͻ 0.05 compared with male rats (2-way repeated-measures ANOVA). MCA diameters were determined as a time-weighted mean. EC50 values are shown in Table 2 .
(see Data Analysis and Calculations). Although the maximal dilation to ATP was similar in all groups (Table 2) , the dilation to 10 Ϫ6 M ATP was significantly lower in ovariectomized female rats with estrogen and vehicle treatment (P Ͻ 0.05 compared with intact male and intact female rats, 2-way repeated-measures ANOVA). Therefore, the EC 50 of MCAs isolated from ovariectomized female rats with both estrogen and vehicle treatment was significantly greater than that of MCAs isolated from intact male and female rats (P Ͻ 0.05, 1-way ANOVA).
To verify that the observed ATP-mediated dilations in MCAs from male and female rats were originating from the endothelium, dilations to 10 Ϫ6 M ATP were assessed before and after removal of the endothelium. As shown in Fig. 3 , removal of the endothelium virtually abolished the dilation to luminal delivery of ATP in MCAs from male and female rats. Integrity of the smooth muscle was confirmed at the end of the experiment with 10 Ϫ5 M SNAP. Denudation constricted MCAs from intact male (12 Ϯ 1%) and female (15 Ϯ 3%) rats to a similar degree. Therefore, removal of the endothelium, another means of eliminating NO, confirmed our L-NAME findings suggesting that basal NO release was similar between MCAs from intact male and female rats. The sensitivity to NO was compared in MCAs isolated from intact male and female rats by running CRCs (10 Ϫ9 -10 Ϫ5 M) to the spontaneous NO donor, MAHMA NONOate, in the presence of L-NAME (3 ϫ 10 Ϫ5 M) to eliminate endogenous sources of NO. Dilations to MAHMA NONOate were similar in MCA from male and female rats (data not shown).
After considering the possibility that ATP could be uniquely degraded to adenosine in the female rat MCA, we challenged these vessels to adenosine (10 Ϫ8 -10 Ϫ4 M CRC). The dilation to adenosine was significantly less than that to ATP (Fig. 4) . Because we observed robust dilations to luminal application of ATP, this suggests that ATP is not degraded to adenosine in our preparation. This has been shown previously in the male rat MCA (19) . After the application of L-NAME and indomethacin, the MCAs constricted by a similar amount between groups: 42 Ϯ 2, 38 Ϯ 3, 40 Ϯ 1, and 39 Ϯ 4% in intact male, intact female, vehicle-treated ovariectomized female, and estrogen-treated ovariectomized female rats, respectively. In the presence of L-NAME and indomethacin, maximal dilation to ATP was similar in intact male and vehicle-treated ovariectomized female rats compared with dilation in the absence of L-NAME and indomethacin. The dilation to ATP in the presence of L-NAME and indomethacin in intact female and estrogen-treated ovariectomized female rats was significantly attenuated (P Ͻ 0.05 compared with male and vehicle-treated ovariectomized female rats, statistical power ϭ 100%, 2-way repeated-measures ANOVA; Fig.  5 ). The EC 50 and maximal dilation were not calculated in these groups, because we did not observe a plateau in the dilation. The EC 50 was significantly shifted to the right in intact male and vehicle-treated ovariectomized female rats (P Ͻ 0.05 compared with all groups in the absence of L-NAME and indomethacin, 1-way ANOVA).
The dynamic response of vessels to 10 Ϫ5 and 10 Ϫ4 M ATP in the presence of L-NAME and indomethacin is shown in Fig. 6 . The response can be very dynamic. For this reason, the integrated mean of the vessel responses was then calculated (see Data Analysis and Calculations). The integrated response to 10 Ϫ5 and 10 Ϫ4 M ATP was significantly lower in intact female and estrogen-treated ovariectomized female rats (P Ͻ 0.05 compared with male and vehicle-treated ovariectomized female rats, 2-way repeated-mea- Values are means Ϯ SE; n, no. of rats. Dose-response curve to ATP was determined in the absence (Ϫ) and presence (ϩ) of N -nitro-Larginine methyl ester (L-NAME) and indomethacin. Concentration to produce half-maximal dilation (EC50) was significantly greater in OVX/E2 and OVX/Vehicle than in intact male and intact female rats: * P Ͻ 0.05 (1-way ANOVA). In the presence of L-NAME and indomethacin, EC50 of male and vehicle-treated ovariectomized female rats was significantly different from all groups in the absence of L-NAME and indomethacin: † P Ͻ 0.05 (1-way ANOVA). EC50 and maximal dilation to ATP in the presence of L-NAME and indomethacin was not calculated in intact female and estrogen-treated ovariectomized female rats, because we did not observe a plateau in the dilation. Ϫ6 M ATP in MCAs isolated from intact male (n ϭ 4) and intact female (n ϭ 4) rats before and after removal of endothelium. Removal of the endothelium virtually abolished dilation to luminal delivery of ATP in MCAs from male and female rats: *P Ͻ 0.05 compared with intact endothelium (repeated-measures ANOVA).
sures ANOVA; Fig. 7) . This confirms the results from our previous analysis in which we used a timeweighted mean. Figure 8 demonstrates that charybdotoxin, an inhibitor of large-conductance K Ca channels, abolished the non-NO component of the dilation at 10 Ϫ5 M ATP and significantly attenuated the dilation at 10 Ϫ4 M ATP in MCAs isolated from intact male and vehicle-treated ovariectomized female rats. The persistent dilation at 10 Ϫ4 M ATP may likely evolve from nonspecific effects of ATP at this concentration, since this effect was observed in male and female rats.
In supplementary studies, we used a distinct P2Y 2 receptor agonist, UTP, to confirm our findings with ATP in the MCA from the intact female rat. Dilations to luminal application of UTP in the presence and absence of L-NAME and indomethacin replicated our findings with ATP (Fig. 4) . Luminal exposure to UDP failed to elicit a dilation and, indeed, produced a constriction (Fig. 4) . The lack of vasodilatory ability of UDP is consistent with that shown previously in the MCA from the male rat (19) .
DISCUSSION
In the present study, we have shown that EDHFmediated dilations to ATP are, for all practical purposes, nonexistent in the female rat MCA. EDHFmediated dilations were significantly enhanced in the ovariectomized female, however, suggesting that estrogen mediates this effect. A number of mechanisms could be mediating this observation in the MCA of the female rat, including the release of EDHF, smooth muscle sensitivity to EDHF, and changes in the halflife of EDHF(s). This is the first study to describe gender-specific differences regarding EDHF-mediated dilations in the cerebrovasculature. In the periphery, there are two reports suggesting that the active release of EDHF to muscarinic receptor stimulation is increased in the female rat mesenteric arterial bed (10, 18) . At the outset, these data may appear to be in conflict with the present data; however, it is important to realize that there are numerous indications that the cellular modes of action of EDHF show tissue and species variability (6) . Although the identity of EDHF remains elusive, it has been defined as 1) being derived from the endothelium, 2) not NO, 3) not prostacyclin or a cyclooxygenase metabolite, 4) hyperpolarizing the vascular smooth muscle, and 5) activating K ϩ channels on the vascular smooth muscle (2, 4, 14) . Possible candidates of EDHF include epoxides, anandamide, K ϩ , and an electrical coupling mediated by myoendothelial gap junctions (7) . Indeed, EDHF may not be a single entity but, rather, a number of factors or, alternatively, a biochemical process. Regardless of the identity of EDHF, its significance has recently received much attention. Upregulation of EDHF has been reported after Fig. 4 . Concentration-response curves in MCAs isolated from intact female rats to luminal application of ATP in the absence (n ϭ 6) and presence (n ϭ 7) of N -nitro-L-arginine methyl ester (L-NAME) and indomethacin, UTP in the absence (n ϭ 3) and presence (n ϭ 4) of L-NAME and indomethacin, adenosine (n ϭ 3), and UDP (n ϭ 4). Dilation to adenosine was significantly reduced compared with dilation to ATP: *P Ͻ 0.05 (2-way repeated-measures ANOVA). Dilation to UDP was significantly reduced compared with dilation to UTP: **P Ͻ 0.05 (2-way repeated-measures ANOVA). . Concentration-response curves to luminal application of ATP in MCAs isolated from intact male (n ϭ 7), intact female (n ϭ 7), estrogen-treated ovariectomized female (n ϭ 7), and vehicle-treated ovariectomized female (n ϭ 9) rats in the presence of L-NAME (3 ϫ 10 Ϫ5 M) and indomethacin (10 Ϫ5 M). Dilation to 10 Ϫ5 and 10 Ϫ4 M ATP was significantly lower in intact female and estrogen-treated ovariectomized female rats: *P Ͻ 0.05 compared with male rats (2-way repeated-measures ANOVA). MCA diameters were determined as a time-weighted mean. EC50 values are shown in Table 2. ischemia-reperfusion (9) and head trauma (6a), suggesting a compensatory role in the absence of NO. There is evidence in the periphery (6) and cerebral circulation (20) that EDHF is a prominent relaxing factor in smaller arteries. However, more work is required to define the significance of EDHF in controlling cerebrovascular function.
It is unknown at this stage why EDHF-mediated dilations are attenuated in the female cerebrovasculature; however, estrogen has been shown to directly activate the large-conductance K ϩ channels (15) . Because these channels play an integral role in mediating EDHF (6), it could be envisaged that estrogen acts to desensitize these channels, thereby contributing to the negligible EDHF-mediated dilations in females.
An interesting finding in the present study is that ovariectomized female rats (with estrogen and vehicle treatment) demonstrated a significantly increased EC 50 compared with male and intact female rats without an effect on the maximal dilation to ATP. This suggests that MCAs isolated from ovariectomized animals have a reduced sensitivity to ATP. The reason for this finding is not known; however, one could speculate that surgical stress and/or anesthesia effects may be Fig. 6 . Dynamic diameter changes of an MCA isolated from an intact male (A) and an intact female (B) rat. In the presence of L-NAME and indomethacin, vessels were exposed to luminal delivery of 10 Ϫ5 and 10 Ϫ4 M ATP and luminal and abluminal application of Ca 2ϩ -free physiological salt solution. Fig. 7 . Integrated response of diameter changes (%change) to luminal application of ATP in MCAs isolated from intact male (n ϭ 7), intact female (n ϭ 7), estrogen-treated ovariectomized female (n ϭ 7), and vehicle-treated ovariectomized female (n ϭ 9) rats in the presence of L-NAME (3 ϫ 10 Ϫ5 M) and indomethacin (10 Ϫ5 M). The integrated response to 10 Ϫ5 and 10 Ϫ4 M ATP was significantly lower in intact female and estrogen-treated ovariectomized female rats: *P Ͻ 0.05 compared with male rats (2-way repeated-measures ANOVA). Ϫ7 M) on dilation to luminal application of ATP in the presence of L-NAME and indomethacin. MCAs were isolated from intact male (n ϭ 3) and vehicle-treated ovariectomized female rats (n ϭ 6). In the presence of charybdotoxin, dilation to 10 Ϫ5 and 10 Ϫ4 M ATP was significantly reduced in intact male and vehicle-treated ovariectomized female rats: *P Ͻ 0.05 compared with animals not treated with charybdotoxin (2-way repeated-measures ANOVA). MCA diameters were calculated using a time-weighted mean.
responsible. Alternatively, replacement with exogenous estrogen and progesterone in ovariectomized animals may prevent these differences; however, further studies are required to verify this hypothesis.
In summary, the present study has shown that EDHF-mediated dilations in the female rat MCA are negligible and that this effect is mediated by estrogen. Although estrogen most likely employs multiple signaling mechanisms to alter vascular physiology in the brain, the present report should set the stage for future studies in this area of investigation.
